* Please be kindly noted that our services and products can only be used for research to organizations or companies and not intended for any clinical or individuals.
KineTAC, short for cytokine receptor-targeting chimera, is an emerging lysosomal targeted protein degradation strategy designed to remove cell-surface membrane proteins and extracellular soluble proteins that are difficult to address with intracellular proteasome-based degraders. Instead of recruiting an E3 ubiquitin ligase, KineTAC molecules use a fully genetically encoded bispecific format: one arm binds the protein of interest (POI), while the other arm presents a natural cytokine or chemokine ligand, such as C-X-C motif chemokine ligand 12 (CXCL12), to engage a cell-surface internalizing receptor such as C-X-C chemokine receptor type 7 (CXCR7, also known as atypical chemokine receptor 3, ACKR3). The resulting ternary complex is internalized and trafficked toward lysosomal compartments, where the target protein can be degraded.
BOC Sciences provides KineTAC technology development services for pharmaceutical, biotechnology, academic, and contract research teams seeking to explore extracellular targeted protein degradation (eTPD) beyond conventional antibody blocking, receptor antagonism, or small-molecule inhibition. Our services cover target feasibility assessment, cytokine receptor selection, antibody or binder arm design, cytokine arm engineering, bispecific construct design, recombinant expression, binding characterization, internalization analysis, lysosomal trafficking validation, degradation profiling, and iterative optimization. By integrating biologics engineering, membrane protein biology, lysosomal degradation assays, and target-specific project design, we help clients build technically grounded KineTAC programs for targets such as PD-L1, HER2, EGFR, VEGF, TNF-α, and other disease-relevant extracellular proteins.
Services
BOC Sciences' Comprehensive KineTAC Technology Development Services
Target Feasibility and Degradability Assessment
A successful KineTAC project begins with determining whether the selected membrane or soluble extracellular protein is suitable for cytokine receptor-mediated lysosomal delivery. We evaluate target localization, extracellular accessibility, disease relevance, abundance, turnover, known antibody or ligand resources, receptor co-expression, internalization context, and assay feasibility to define whether KineTAC is an appropriate degradation strategy.
Cell-surface and extracellular target biology assessment
Evaluation of POI accessibility, epitope location, and expression models
Identification of assay systems for target quantification, internalization, and degradation readouts
Cytokine Receptor and Internalization Route Selection
The cytokine arm is the core driver of receptor engagement and intracellular trafficking in KineTAC design. We help clients select and evaluate cytokine-receptor pairs based on receptor expression, internalization capacity, recycling behavior, target-cell context, and compatibility with the POI-binding arm. For CXCL12-based designs, we assess CXCR7-mediated uptake and lysosomal routing as a starting strategy; for broader projects, we compare alternative cytokine, chemokine, or growth factor receptor routes.
CXCL12-CXCR7 internalization strategy assessment
Cytokine, chemokine, and receptor expression profiling support
Receptor-mediated uptake route comparison for cell-type-focused degradation
Early risk evaluation for receptor competition, ligand geometry, and pathway context
Antibody, Binder, and Target-Recognition Arm Design
Target-binding arm quality strongly affects KineTAC degradation efficiency. We support antibody fragment, single-domain binder, peptide binder, and other recognition element design with attention to epitope position, binding affinity, target residence time, pH-dependent dissociation, steric distance from the cell membrane, and compatibility with receptor-driven internalization. This helps clients avoid nonproductive binders that recognize the target but fail to support efficient lysosomal delivery.
Binder selection and epitope suitability evaluation
Comparison of antibody, fragment, peptide, and engineered binder options
Design logic for membrane-proximal and soluble target engagement
KineTAC Construct Engineering and Bispecific Design
KineTAC molecules require coordinated engineering of the target-binding arm, cytokine arm, Fc architecture, linker orientation, expression cassette, and purification strategy. BOC Sciences designs recombinant KineTAC constructs with attention to arm geometry, cytokine accessibility, target-binding valency, expression yield, aggregation tendency, and functional compatibility in cell-based assays.
Design of construct panels for parallel cytokine-arm and binder-arm comparison
Binding, Receptor Engagement, and Complex Formation Analysis
KineTAC activity depends on simultaneous engagement of the POI and the internalizing cytokine receptor. We provide binding characterization workflows to evaluate affinity, avidity, receptor engagement, target binding under relevant pH conditions, and ternary complex formation potential. These studies help determine whether weak degradation is caused by insufficient target binding, poor receptor recruitment, or unfavorable molecular geometry.
POI binding and cytokine receptor binding characterization
Target-receptor co-engagement and bispecific binding analysis
Assessment of pH-dependent release behavior and binding durability
KineTAC In Vitro and Cell-Based Degradation Evaluation
We establish cell-based workflows to measure KineTAC-mediated internalization, lysosomal trafficking, target depletion, degradation kinetics, and functional pathway response. Depending on the target and project stage, readouts may include flow cytometry, immunofluorescence imaging, Western blot, enzyme-linked immunosorbent assay (ELISA), target-specific immunoassays, receptor competition studies, and lysosomal pathway confirmation.
Cell-surface protein degradation assays for PD-L1, HER2, EGFR, and related targets
Soluble protein uptake and depletion evaluation for VEGF, TNF-α, and cytokine-like targets
KineTAC development requires more than joining a cytokine to an antibody. The project outcome depends on target accessibility, cytokine receptor biology, epitope location, construct geometry, recombinant expression quality, cellular uptake behavior, and lysosomal degradation confirmation. BOC Sciences provides integrated solutions that connect design logic with experimental evidence, helping clients make confident technical decisions at each stage.
Solution for Target and Receptor Feasibility
Many extracellular targets appear attractive but lack the membrane proximity, receptor co-expression, or internalization context required for efficient KineTAC degradation. We address this by evaluating target distribution, extracellular domain accessibility, receptor expression, internalization capacity, disease-pathway relevance, and assay model availability. This analysis helps clients determine whether a CXCL12-CXCR7 design, another cytokine receptor route, or an alternative lysosomal degradation modality is more appropriate.
Solution for Binder Arm and Epitope Optimization
A binder can show strong affinity but still fail to drive degradation if it binds an unfavorable epitope or creates a nonproductive distance between the target and the internalizing receptor. We compare candidate binders by epitope location, binding orientation, pH behavior, affinity window, and cellular target occupancy. When necessary, we support alternative binder discovery or redesign to improve productive POI-receptor proximity and lysosomal delivery.
Solution for Construct Design and Expression Quality
KineTAC molecules are recombinant bispecific proteins, so expression format and structural architecture are central to project success. We optimize cytokine-arm orientation, linker spacing, Fc configuration, valency, construct stability, and purification strategy. By generating focused construct panels instead of relying on a single design, clients can rapidly compare activity-driving variables and identify the format with the best balance of expression quality and degradation function.
Solution for Mechanistic Validation and Data Interpretation
A reduction in detectable target signal may reflect true degradation, internalization without degradation, epitope masking, shedding, or nonspecific cellular changes. To clarify mechanism, we design validation studies using time-course profiling, receptor competition, lysosomal pathway modulation, co-localization imaging, target quantification, and soluble protein uptake analysis. This enables clients to distinguish productive KineTAC-mediated degradation from misleading assay signals.
Choose BOC Sciences to Build More Reliable KineTAC Degradation Programs!
From extracellular target feasibility and cytokine receptor strategy to recombinant KineTAC design, expression, binding characterization, internalization assays, and lysosomal degradation validation, BOC Sciences provides tailored support for next-generation extracellular targeted protein degradation projects. Our interdisciplinary platform helps clients reduce design uncertainty, generate actionable data, and advance KineTAC programs with stronger technical confidence.
Our KineTAC Solutions Support Diverse R&D Organizations
Research Institutes and Academic Laboratories
Academic groups use KineTAC technology to investigate extracellular degradation biology, receptor-mediated internalization, lysosomal trafficking, and target dependency. We support exploratory projects with flexible modules covering target assessment, construct design, recombinant protein preparation, and mechanism-focused cellular assays.
Biotechnology Companies
Biotechnology teams often need rapid proof-of-concept data to determine whether a cell-surface or soluble extracellular target can be removed through cytokine receptor-mediated lysosomal degradation. BOC Sciences helps accelerate early decisions through focused design panels, degradation assays, and practical optimization recommendations.
Pharmaceutical Discovery Teams
Pharmaceutical discovery teams can use KineTAC development to explore degradation strategies for oncology, inflammatory signaling, immune checkpoint, receptor tyrosine kinase, and extracellular mediator targets. We provide systematic support across binder selection, receptor strategy, assay design, and degradation-data interpretation.
CROs / Technical Service Platforms
CROs and technical platforms may require specialized KineTAC expertise to complement internal antibody engineering, protein production, or cellular assay capabilities. We offer modular collaboration models covering construct design, recombinant expression, binding analysis, internalization studies, and lysosomal degradation evaluation.
End-to-End KineTAC Technology Development Workflow
01
Inquiry and Requirement Collection
Understand the client's target protein, target format, available antibody or binder resources, desired cell models, receptor preferences, degradation readouts, and project-stage objectives.
02
Target and Receptor Feasibility Assessment
Evaluate target accessibility, expression profile, extracellular domain features, cytokine receptor co-expression, internalization potential, and assay feasibility to define a practical KineTAC strategy.
03
Binder Arm and Cytokine Arm Design
Select or engineer the POI-binding arm and cytokine receptor-engaging arm, considering affinity, epitope location, receptor biology, construct geometry, and trafficking behavior.
04
Bispecific Construct Design and Project Scope Definition
Prepare a tailored construct panel covering fusion orientation, Fc architecture, linker design, valency, expression format, assay package, and decision points for optimization.
05
Recombinant Expression and Purification
Produce KineTAC constructs, evaluate expression quality, perform purification, and assess basic protein attributes needed for downstream binding and cellular assays.
06
Binding and Receptor Engagement Characterization
Measure POI binding, receptor engagement, bispecific co-binding, pH-dependent behavior, and target-receptor complex formation potential.
07
Internalization and Lysosomal Degradation Validation
Refine binder selection, cytokine receptor strategy, construct architecture, assay conditions, and degradation interpretation, then provide clear data packages and next-step recommendations.
Advantages
Advantages of KineTAC Technology
Targets Extracellular Biology
KineTAC technology expands degradation beyond intracellular proteins by enabling removal of cell-surface and soluble extracellular proteins, including targets that are poorly suited for proteasome-based degradation approaches.
Uses Lysosomal Delivery
By recruiting internalizing cytokine receptors, KineTAC molecules can redirect target proteins toward endolysosomal trafficking and lysosomal degradation rather than only blocking ligand-receptor interaction.
Fully Genetically Encoded Format
KineTACs can be designed as recombinant bispecific proteins, allowing modular exchange of target-binding arms and cytokine receptor-engaging arms without requiring complex small-molecule conjugation chemistry.
High Modularity and Customization
Different antibodies, binders, cytokines, chemokines, receptor routes, and construct architectures can be evaluated to tailor KineTAC behavior for specific targets, cell types, and degradation objectives.
Applications
Applications Supported by Our KineTAC Technology Platform
Immune Checkpoint and Oncology Target Degradation
KineTAC design for cell-surface proteins such as PD-L1, HER2, EGFR, and related oncology-associated membrane targets
Evaluation of target removal versus receptor blockade or antibody-only modulation
Internalization and lysosomal trafficking studies in tumor-relevant cellular models
Integration with PROTAC targeting EGFR research knowledge when comparing intracellular and extracellular target strategies
Soluble Cytokine and Growth Factor Depletion
Development of KineTAC concepts for soluble extracellular proteins such as VEGF, TNF-α, and inflammatory mediators
Assessment of target capture, cellular uptake, lysosomal routing, and extracellular protein depletion
Assay design for soluble protein concentration changes in conditioned media or cell-based systems
Support for immune signaling, angiogenesis, and inflammatory pathway research
Extracellular Targeted Protein Degradation Platform Comparison
Comparison of KineTAC with other lysosomal degradation strategies for extracellular targets
Evaluation of receptor route, target format, binder availability, and degradation mechanism
Support for biologics teams exploring degradation rather than neutralization alone
Case Study
Client Success Stories: KineTAC Technology Development
Project Background
A biotechnology research team wanted to explore whether a PD-L1-binding antibody fragment could be converted into a KineTAC molecule capable of reducing cell-surface PD-L1 abundance rather than simply blocking ligand interaction. The client had a binder with confirmed PD-L1 affinity but lacked experience in cytokine receptor selection, recombinant bispecific design, and degradation-mechanism validation.
Our Support
We first reviewed the PD-L1 binder sequence, binding epitope information, and cellular models with measurable PD-L1 and CXCR7 expression. Based on this feasibility assessment, we designed 12 KineTAC constructs using a CXCL12-derived cytokine arm, two Fc fusion orientations, and three flexible linker designs between the cytokine and scaffold region. After recombinant expression and purification, we compared PD-L1 binding, CXCR7 engagement, and dual-binding behavior. In the first cell-based screen, two constructs showed strong surface binding but limited degradation, suggesting that the target-binding orientation was not favorable for receptor-mediated uptake. We then redesigned the fusion orientation and selected a construct with improved internalization signal within 4 h and stronger lysosomal co-localization at 8 h. Under optimized assay conditions, the lead construct achieved reproducible PD-L1 reduction with Dmax above 60% in a CXCR7-positive cell model, while receptor competition reduced the degradation effect, supporting a receptor-dependent mechanism.
Client Testimonial
BOC Sciences helped us move from a general KineTAC idea to a structured design-and-validation campaign. Their ability to connect binder geometry, receptor engagement, and degradation assays gave us a clear path for continued optimization.
Project Background
A drug discovery group studying inflammatory signaling wanted to evaluate whether a soluble TNF-α-binding module could support cytokine capture and lysosomal delivery through a KineTAC-like strategy. The key challenge was not only demonstrating TNF-α binding, but also proving that the soluble target could be internalized and depleted in a receptor-dependent manner.
Our Support
We designed a focused panel of 10 KineTAC constructs combining two TNF-α-binding formats with CXCL12-based receptor recruitment and varied linker spacing. Before degradation testing, we characterized target binding and confirmed that three constructs retained strong TNF-α recognition after fusion. We then established a soluble target uptake assay using fluorescently labeled TNF-α, receptor-positive cells, and time points at 1 h, 4 h, and 16 h. Initial constructs captured TNF-α but showed only moderate uptake, so we adjusted linker spacing and reduced steric interference near the cytokine arm. The optimized design improved intracellular TNF-α signal accumulation and produced a measurable reduction of extracellular TNF-α in the assay medium. Lysosomal co-localization and receptor competition experiments further supported productive receptor-mediated uptake, giving the client a validated construct architecture for next-round binder and receptor-route optimization.
Client Testimonial
The BOC Sciences team helped us understand which design variables controlled soluble target uptake. The project generated practical data on construct format, receptor dependence, and assay conditions that we could directly use for the next development cycle.
Why Us
Why Choose BOC Sciences for Your KineTAC Project?
Integrated KineTAC Development Support
We provide coordinated support across target assessment, cytokine receptor strategy, binder design, recombinant construct engineering, binding assays, cellular uptake studies, and degradation validation.
Expertise in Lysosomal Degradation Biology
Our team understands how receptor-mediated endocytosis, lysosomal trafficking, epitope geometry, and extracellular protein biology influence KineTAC performance.
Flexible Modular Service Models
Clients can request focused modules such as binding characterization or degradation assays, or choose end-to-end KineTAC development from feasibility analysis to optimized construct selection.
Recombinant Biologics Engineering Capability
We support bispecific format design, cytokine arm engineering, binder fusion strategy, expression planning, purification, and construct comparison for genetically encoded KineTAC molecules.
Mechanism-Focused Validation
Our workflows help determine whether target reduction is consistent with receptor-mediated internalization and lysosomal degradation rather than nonspecific signal loss.
Clear Reporting and Optimization Guidance
We provide organized experimental data, practical interpretation, construct-level comparison, and next-step recommendations to support KineTAC optimization decisions.
KineTAC (cytokine receptor‑targeting chimera) technology is a fully genetically encoded bifunctional platform designed for targeted degradation of extracellular and membrane proteins. KineTAC molecules combine a natural cytokine ligand that binds a specific receptor with an antibody arm targeting the protein of interest. This complex triggers receptor-mediated internalization and lysosomal degradation, enabling modulation of targets beyond the scope of intracellular PROTACs or SNIPERs.
How does KineTAC differ from other degradation modalities?
Unlike PROTACs, which recruit intracellular E3 ubiquitin ligases for proteasomal degradation, KineTACs utilize cytokine receptor-mediated endocytosis and the lysosomal pathway. They are fully genetically encoded and bypass chemical conjugation, using natural receptor trafficking to deliver the target protein for degradation. This allows selective targeting of soluble or membrane-bound proteins that conventional intracellular degraders cannot reach.
What kinds of targets can be degraded using KineTACs?
KineTACs are capable of degrading extracellular proteins, such as cytokines or growth factors, as well as membrane proteins including receptor tyrosine kinases and immune checkpoints. Preclinical studies demonstrate degradation of targets like PD-L1, EGFR, and VEGF. This expands the druggable proteome by addressing molecules that are typically inaccessible to proteasome-recruiting PROTACs and allows research into previously untargetable signaling pathways.
What are the main advantages of KineTAC technology for drug discovery?
Key advantages of KineTAC include the ability to target extracellular and membrane proteins, fully genetically encoded design avoiding chemical conjugation, and exploitation of natural cytokine receptor internalization. It is modular, allowing receptor selection for cell-type specificity, and provides an alternative degradation route to E3 ligase-dependent strategies. This combination increases flexibility in preclinical development and expands the range of potential therapeutic targets.
What challenges remain in developing KineTAC therapeutics?
Despite its potential, KineTAC development faces several challenges. These include optimizing expression and stability of diverse cytokine-antibody chimeras, achieving efficient internalization and lysosomal routing across different cell types, and fully understanding pharmacokinetics and biodistribution. Additionally, designing optimal cytokine-receptor combinations for disease-specific applications requires careful validation and iterative testing to ensure reliable degradation outcomes.
Quick Inquiry
BOC Sciences Support
Please contact us with any specific requirements and we will get back to you as soon as possible.
We invite you to contact us at or through our contact form above for more information about our services and products.
Targets Extracellular Biology
